FindTrial
Sign In

EC50 of Remifentanil for Inhibiting Responses to Tracheal Intubation in Patients treated by different doses of oliceridine

EC50 of Remifentanil for Inhibiting Responses to Tracheal Intubation in Patients treated by different doses of oliceridine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400094931
Enrollment
Unknown
Registered
2024-12-30
Start date
2025-01-01
Completion date
Unknown
Last updated
2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Blank control group:None
Sufentanil group:Sufentanil
Oceridine 0.015mg/kg group:Oliceridine
Oxelidine 0.03mg/kg group:Oliceridine

Sponsors

The First Affiliated Hospital of the Naval Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: 1. Patients who intend to undergo thyroidectomy under elective general anesthesia; 2. Age 18~64 years old; 3. BMI 18.5~30kg/m2, weight < 100kg; 4. ASA is graded as I-II; 5. The patient voluntarily participated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Anticipated difficult airway; 2.Presence of severe heart, lung, liver, kidney, or brain disease before surgery; 3.Patients on long-term opioid medication treatment, drug abuse, or drug addiction; 4.Pregnancy status.

Design outcomes

Primary

MeasureTime frame
Remifentanil's half maximal effective concentration (EC50);—

Secondary

MeasureTime frame
Postoperative airway complications such as hoarseness, sore throat, and difficulty in pronunciation;Nausea and vomiting;Intraoperative awareness;Anesthesia induction time;—

Countries

China

Contacts

Public ContactWang Jiafeng

The First Affiliated Hospital of the Naval Medical University

feng_smmu@hotmail.com+86 21 31161846

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026